Risk factors in the development of multiple sclerosis

Expert Review of Clinical Immunology

Volumn 3, Issue 5, 2007, Pages 739-748

  Munger, Kassandra L ^a   Ascherio, Alberto ^a  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CELL NUCLEUS ANTIGEN; IMMUNOGLOBULIN G; VITAMIN D;

CENTRAL NERVOUS SYSTEM DISEASE; CIGARETTE SMOKING; DEMYELINATING DISEASE; DIETARY INTAKE; DISEASE ASSOCIATION; DRUG DOSE INCREASE; EPIDEMIOLOGICAL DATA; EPSTEIN BARR VIRUS; GENETIC SUSCEPTIBILITY; HUMAN; MULTIPLE SCLEROSIS; REVIEW; RISK ASSESSMENT; SUN EXPOSURE; T LYMPHOCYTE; VIRUS INFECTION; VITAMIN BLOOD LEVEL; VITAMIN SUPPLEMENTATION;

EID: 34648817202     PISSN: 1744666X     EISSN: None     Source Type: Journal    
DOI: 10.1586/1744666X.3.5.739     Document Type: Review

References (111)

1. Ascherio A, Munger KL. Multiple sclerosis. In: Neuroepidemiology From Principles to Practice. Nelson LM, Tanner CM, Van Den Eeden SK, McGuire VM (Eds). Oxford University Press, Oxford, UK 188-222 (2004).
2. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc. Natl Acad. Sci. USA 100, 12877-12882 (2003).
3. Hansen T, Skytthe A, Stenager E et al. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult. Scler. 11, 504-510 (2005).
4. Schmidt H, Williamson D, Ashley-Koch A. HLA-DR15 Haplotype and multiple sclerosis: A HuGE review. Am. J. Epidemiol. 165(10), 1097-1109 (2007).
5. Gale CR, Martyn CN. Migrant studies in multiple sclerosis. Prog. Neurobiol. 47, 425-448 (1995).
6. Hammond SR, English DR, McLeod JG. The age-range of risk of developing multiple sclerosis: evidence from a migrant population in Australia. Brain 123(Pt 5), 968-974 (2000).
7. Ascherio A, Munger K. Environmental risk factors for multiple sclerosis: part I - the role of infection. Ann. Neurol. 61 (4), 288-299 (2007).
8. Ascherio A, Munger K. Environmental risk factors for multiple sclerosis: part II - non-infectious factors. Ann. Neurol. 61 (6), 504-513 (2007).
9. Hernan MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology 53, 1711-1718 (1999).
10. Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-yeas follow-up. Mult. Scler. 5, 293-296 (1999).
11. Anderson DW, Hlenberg JH, Leventhal CM et al. Revised estimate of the prevalence of multiple sclerosis in the United States. Ann. Neurol. 31, 333-336 (1992).
12. Kurtzke JF, Beebe GW, Norman JE. Epidemiology of multiple sclerosis in U.S. veterans: 1. Race, sex, and geographic distribution. Neurology 29, 1228-1235 (1979).
13. Kurtzke JF, Page WF. Epidemiology of multiple sclerosis in US veterans: VII. Risk factors for MS. Neurology 48, 204-213 (1997).
14. Miller DH, Hammond SR, McLeod JG, Purdie G, Skegg DC. Multiple sclerosis in Australia and New Zealand: are the determinants genetic or environmental? J. Neurol. Neurosurg. Psychiatry 53, 903-905 (1990).
15. Bulman DE, Ebers GC. The geography of MS reflects genetic susceptibility. J. Trop. Geogr. Neurol. 2, 66-72 (1992).
16. Page WF, Kurtzke JF, Murphy FM, Norman JE Jr. Epidemiology of multiple sclerosis in U.S. veterans: V. Ancestry and the risk of multiple sclerosis. Ann. Neurol. 33, 632-639 (1993).
17. Kurtzke JF, Beebe GW, Norman JE. Epidemiology of multiple sclerosis in US veterans: III. Migration and the risk of MS. Neurology 35, 672-678 (1985).
18. Wallin MT, Page WF, Kurtzke JE Multiple sclerosis in US veterans of the Vietnam era and later military service: race, sex, and geography. Ann. Neurol. 55, 65-71 (2004).
19. Warner HB, Carp RI. Multiple sclerosis and Epstein-Barr virus. Lancet 2, 1290 (1981).
20. Niederman J, Evans A. Epstein-Barr virus. In: Viral Infections of Humans: Epidemiology and Control. Kaslow EA (Ed.). Plenum Medical Book Co., NY, USA 253-283 (1997).
21. Kurtzke JF. A reassessment of the distribution of multiple sclerosis. Part one. Acta Neurol. Scand. 51, 110-136 (1975).
22. Beebe GW, Kurtzke JF, Kurland LT, Auth TL, Nagler B. Studies on the natural history of multiple sclerosis. 3. Epidemiologic analysis of the Army experience in World War II. Neurology 17, 1-17 (1967).
23. Operskalski EA, Visscher BR, Malmgren RM, Detels R. A case-control study of multiple sclerosis. Neurology 38, 825-829 (1989).
24. Souberbielle BE, Martin-Mondiere C, O'Brien ME et al. A case control epidemiological study of MS in the Paris area with particular reference to past disease history and profession. Acta Neurol. Scand. 82, 303-310 (1990).
25. Hopkins RS, Indian RW, Pinnow E, Conomy J. Multiple sclerosis in Galion, Ohio: prevalence and results of a case-control study. Neuroepidemiology 10, 192-199 (1991).
26. Martyn CN, Cruddas M, Compston D. Symptomatic Epstein-Barr virus infection and multiple sclerosis. J. Neurol. Neurosurg. Psychiatry 56, 167-168 (1993).
27. Casetta I, Granieri E, Malagu S et al. Environmental risk factors and multiple sclerosis: a community-based, case-control study in the province of Ferrara, Italy. Neuroepidemiology 13, 120-128 (1994).
28. Gusev E, Boiko A, Lauer K, Riise T, Deomina T. Environmental risk factors in MS: a case-control study in Moscow. Acta Neurol. Scand. 94, 386-394 (1996).
29. Marrie RA, Wolfson C, Sturkenboom MC et al. Multiple sclerosis and antecedent infections: a case-control study. Neurology 54, 2307-2310 (2000).
30. Hernan MA, Zhang SM, Lipworth L, Olek MJ, Ascherio A. Multiple sclerosis and age at infection with common viruses. Epidemiology 12, 301-306 (2001).
31. Zorzon M, Zivadinov R, Nasuelli D et al. Risk factors of multiple sclerosis: a case-control study. Neurol. Sci. 24, 242-247 (2003).
32. Haahr S, Plesner AM, Vestergaard BF, Hollsberg P. A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurol. Scand. 109, 270-275 (2004).
33. Ponsonby AL, van der Mel I, Dwyer T et al. Exposure to infant siblings during early life and risk of multiple sclerosis. JAMA 293, 463-469 (2005).
34. Lindberg C, Andersen O, Vahlne A, Dalton M, Runmarker B. Epidemiological investigation of the association between infectious mononucleosis and multiple sclerosis. Neuroepidemiology 10, 62-65 (1991).
35. Haahr S, Koch-Henriksen N, Moller-Larsen A, Eriksen LS, Andersen HM. Increased risk of multiple sclerosis after late Epstein-Barr virus infection: a historical prospective study. Mult. Scler. 1, 73-77 (1995).
36. Goldacre MJ, Wotton CJ, Seagroatt V, Yeates D. Muldple sclerosis after infectious mononucleosis: record linkage study. J. Epidemiol. Community Health 58, 1032-1035 (2004).
37. Thacker EL, Mirzaei F, Ascherio A. Infectious mononucleosis and risk for multiple sclerosis: a meta-analysis. Ann. Neurol. 59, 499-503 (2006).
38. Nielsen TR, Rostgaard K, Nielsen NM et al. Multiple sclerosis after infectious mononucleosis. Arch. Neurol. 64, 72-75 (2007).
39. Sumaya CV, Myers LW, Ellison GW. Epstein-Barr virus antibodies in multiple sclerosis. Arch. Neurol. 37, 94-96 (1980).
40. Bray PF, Bloomer LC, Salmon VC, Bagley MH, Larsen PD. Epstein-Barr virus infection and antibody synthesis in patients with multiple sclerosis. Arch. Neurol. 40, 406-408 (1983).
41. Larsen PD, Bloomer LC, Bray PF. Epstein-Barr nuclear antigen and viral capsid antigen antibody titers in multiple sclerosis. Neurology 35, 435-438 (1985).
42. Sumaya CV, Myers LW, Ellison GW, Ench Y. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann. Neurol. 17, 371-377 (1985).
43. Shirodaria PV, Haire M, Fleming E et al. Viral antibody titers. Comparison in patients with multiple sclerosis and rheumatoid arthritis. Arch. Neurol. 44, 1237-1241 (1987).
44. Ferrante P, Castellani P, Barbi M, Bergamini F. The Italian Cooperative Multiple Sclerosis case-control study: preliminary results on viral antibodies. Ital. J. Neurol. Sci. Suppl. 6, 45-50 (1987).
45. Munch M, Hvas J, Christensen T, Moller-Larsen A, Haahr S. The implications of Epstein-Barr virus in multiple sclerosis - a review. Acta Neurol. Scand. Suppl. 169, 59-64 (1997).
46. Myhr KM, Riise T, Barrett-Connor E et al. Altered antibody pattern to Epstein-Barr virus but not to other herpesviruses in multiple sclerosis: a population based case-control study from western Norway. J. Neurol. Neurosurg. Psychiatry 64, 539-542 (1998).
47. Ascherio A, Munch M. Epstein-Barr virus and multiple sclerosis. Epidemiology 11, 220-224 (2000).
48. Wagner HJ, Hennig H, Jabs WJ et al. Altered prevalence and reactivity of anti-Epstein-Barr virus antibodies in patients with multiple sclerosis. Viral Immunol. 13, 497-502 (2000).
49. Ascherio A, Munger KL, Lennette ET et al. Epstein-Barr virus antibodies and risk of multiple sclerosis: a prospective study. JAMA 286, 3083-3088 (2001).
50. Sundstrom P, Juto P, Wadell G et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: a prospective study. Neurology 62, 2277-2282 (2004).
51. Levin LI, Munger KL, Rubertone MV et al. Temporal relationship between elevation of Epstein-Barr virus antibody titers and initial onset of neurological symptoms in multiple sclerosis. JAMA 293, 2496-2500 (2005).
52. DeLorenze GN, Mtmger KL, Lennette E et al. Epstein-Barr virus and multiple sclerosis: evidence of association from a prospective study with long-term follow-up. Arch. Neurol. 63, 839-844 (2006).
53. Alotaibi S, Kennedy J, Tellier R, Stephens D, Banwell B. Epstein-Barr virus in pediatric multiple sclerosis. JAMA 291, 1875-1879 (2004).
54. Pohl D, Krone B, Rostasy K et al. High seroprevalence of Epstein-Barr virus in children with multiple sclerosis. Neurology 67, 2063-2065 (2006).
55. Lang HL, Jacobsen H, Ikemizu S et al. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol. 3, 940-943 (2002).
56. + T cell responses to selected Epstein-Barr virus immunodominant epitopes in patients with multiple sclerosis. Clin. Exp. Immunol. 132, 137-143 (2003).
57. + T cells from a multiple sclerosis patient cross-recognize Epstein-Barr virus and myelin basic protein. J. Neurovirol. 10, 278-283 (2004).
58. Lunemann JD, Edwards N, Muraro PA et al. Increased frequency and broadened specifidty of latent EBV nuclear antigen-1-specific T cells in multiple sclerosis. Brain 129, 1493-1506 (2006).
59. Rand KH, Houck H, Denslow ND, Heilman KM. Epstein-Barr virus nuclear antigen-1 (EBNA-1) associated oligodonal bands in patients with multiple sclerosis. J. Neurol. Sci. 173, 32-39 (2000).
60. Cepok S, Zhou D, Srivastava R et al. Identification of Epstein-Barr virus proteins as putative targets of the immune response in multiple sclerosis. J. Clin. Invest. 115, 1352-1360 (2005).
61. Sutkowski N, Palkama T, Ciurli C et al. An Epstein-Barr virus-associated superantigen. J. Exp. Med. 184, 971-980 (1996).
62. van Sechel AC, Bajramovic JJ, van Stipdonk MJ et al. EBV-induced expression and HLA-DR-restricted presentation by human B cells of α B-crystallin, a candidate autoantigen in multiple sclerosis. J. Immunol. 162, 129-135 (1999).
63. Pender MP. Infection of autoreactive B lymphocytes with EBV, causing chronic autoimmune diseases. Trends Immunol. 24, 584-588 (2003).
64. Goldberg P. Multiple sclerosis: vitamin D and calcium as environmental determinants of prevalence (a viewpoint). Part 1: sunlight, dietary factors and epidemiology. Intern. J. Environmental Studies 6, 19-27 (1974).
65. Holick ME Sunlight and vitarnin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am. J. Clin. Nutr. 80, 1678S-1688S (2004).
66. Webb AR, Kline L, Holick ME Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J. Clin. Endocrinol. Metab. 67, 373-378 (1988).
67. Acheson ED, Bachrach CA, Wright FM. Some comments on the relationship of the distribution of multiple sclerosis to latitude, solar radiation, and other variables. Acta Psychiatr. Scand. 35(Suppl. 147), 132-147 (1960).
68. Wang F, Gregory C, Sample C et al. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. J. Virol. 64, 2309-2318 (1990).
69. Norman JE, Kurtzke JF, Beebe GW. Epidemiology of multiple sclerosis in U.S. veterans: 2. Latitude, climate and the risk of multiple sclerosis. J. Chron. Dis. 36, 551-559 (1983).
70. van der Mel IA, Ponsonby AL, Blizzard L, Dwyer T. Regional variation in multiple sclerosis prevalence in Australia and its association with ambient ultraviolet radiation. Neuroepidemiology 20, 168-174 (2001).
71. Freedman DM, Dosemeci M, Alavanja MC. Mortality from multiple sclerosis and exposure to residential and occupational solas radiation: a case-control study based on death certificates. Occup. Environ. Med. 57, 418-421 (2000).
72. Goldacre MJ, Seagroatt V, Yeates D, Acheson ED. Skin cancer in people with multiple sclerosis: a record linkage study. J. Epidemiol. Community Health 58, 142-144 (2004).
73. Antonovsky A, Leibowitz U, Smith HA et al. Epidemiologic study of multiple sclerosis in Israel. I. An overall review of methods and findings. Arch. Neurol. 13, 183-193 (1965).
74. Cendrowski W, Wender M, Dominik W et al. Epidemiological study of multiple sclerosis in western Poland. Eur. Neurol. 2, 90-108 (1969).
75. van der Mei IA, Ponsonby AL, Dwyer T et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: case-control study. Br. Med. J. 327, 316-321 (2003).
76. Kampman MT, Wilsgaard T, Mellgren SI. Outdoor activities and diet in childhood and adolescence relate to MS risk above the Arctic Circle. J. Neurol. 254, 471-477 (2007).
77. Lucas RM, Ponsonby AL. Considering the potential benefits as well as adverse effects of sun exposure: can all the potential benefits be provided by oral vitamin D supplementation? Prog. Biophys. Mol. Biol. 92, 140-149 (2006).
78. Aubin F. Mechanisms involved in ultraviolet light-induced immunosuppression. Eur. J. Dermatol. 13, 515-523 (2003).
79. Munger KL, Zhang SM, O'Reilly E et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 62, 60-65 (2004).
80. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 296, 2832-2838 (2006).
81. Swank RL, Lerstad O, Strom A, Backer J. Multiple sclerosis in rural Norway its geographic and occupational incidence in relation to nutrition. N. Engl. J. Med. 246, 722-728 (1952).
82. Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol. Scand. 46, 455-483 (1970).
83. Willett WC. Nutritional Epidemiology (Second Edition). Oxford University Press, Inc., NY, USA (1998).
84. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 44, 1687-1692 (1994).
85. Cosman F, Nieves J, Komar L et al. Fracture history and bone loss in patients with MS. Neurology 51, 1161-1165 (1998).
86. Soilu-Hanninen M, Airas L, Mononen I et al. 25-Hydroxyvitamin D levels in serum at the onset of multiple sclerosis. Mult. Scler. 11, 266-271 (2005).
87. Ozgocmen S, Bulut S, Ilhan N et al. Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity. J. Bone Miner. Metab. 23, 309-313 (2005).
88. van der Mei IA, Ponsonby AL, Dwyer T et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J. Neurol. 254, 581-590 (2007).
89. Rubertone MV, Brundage JF. The Defense Medical Surveillance System and the Department of Defense serum repository: glimpses of the future of public health surveillance. Am. J. Public Health 92, 1900-1904 (2002).
90. Hayes CE, Nashold FE, Spach KM, Pedersen LB. The immunological functions of the vitamin D endocrine system. Cell. Mol. Biol. (Noisy-le-grand) 49, 277-300 (2003).
91. Lemire JM, Archer DC. 1,25-dihydroxyvitamin D3 prevents the in vivo inducrion of murine experimental autoimmune encephalomyelitis. J. Clin. Invest. 87, 1103-1107 (1991).
92. Cantoma MT, Hayes CE, DeLuca HF. 1,25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Nad Acad. Sci. USA 93, 7861-7864 (1996).
93. Spach KM, Hayes CE. Vitamin D3 confers protection from autoimmune encephalomyelitis only in female mice. J. Immunol. 175, 4119-4126 (2005).
94. D'Ambrosio D, Cippitelli M, Cocciolo MG et al. Inhibition of IL- 12 producdon by 1,25-dihydroxyviramin D3. Involvement of NF-κB downregulation in transcriptional repression of the p40 gene. J. Clin. Invest. 101, 252-262 (1998).
95. Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25-dihydroxyvitamin D3: preferential inhibition of Thl functions. J. Nutr. 125, 1704S-1708S (1995).
96. Reichel H, Koeffier HP, Tobler A, Norman AW. 1 α,25-dihydroxyvitamin D3 inhibits γ-interferon synthesis by normal human peripheral blood lymphocytes. Proc. Natl Acad. Sci. USA 84, 3385-3389 (1987).
97. Rigby WF, Noelle RJ, Krause K, Fanger MW. The effects of 1,25-dihydroxyvitamin D3 on human T lymphocyte activation and proliferation: a cell cycle analysis. J. Immunol. 135, 2279-2286 (1985).
98. Cantorna MT, Woodward WD, Hayes CE, DeLuca HE 1,25-dihydroxyvitamin D3 is a positive regulator for the two anti-encephalitogenic cytokines TGF-β 1 and IL-4. J. Immunol. 160, 5314-5319 (1998).
99. Nashold FE, Hoag KA, Goverman J, Hayes CE. Rag-l-dependent cells are necessary for 1,25-dihydroxyvitamin D(3) prevention of experimental autoimmune encephalomyelitis. J. Neuraimmunol. 119, 16-29 (2001).
100. + regulatory T cells in patients wirh multiple sclerosis. J. Exp. Med. 199, 971-979 (2004).
101. Ghadirian P, Dadgostar B, Azani R, Maisonneuve P. A case-control study of the association between socio-demographic, lifestyle and medical history factors and multiple sclerosis. Can. J. Public Health 92, 281-285 (2001).
102. Warren SA, Warren KG, Greenhill S, Paterson M. How multiple sclerosis is related to animal illness, stress and diabetes. Can. Med. Assoc. J. 126, 377-382, 385 (1982).
103. Riise T, Nortvedt MW, Ascherio A. Smoking is a risk factor for multiple sclerosis. Neurology 61, 1122-1124 (2003).
104. Villard-Mackintosh L, Vessey ME Oral contraceptives and reproductive factors in multiple sclerosis incidence. Cantraception 47, 161-168 (1993).
105. Thorogood M, Hannaford PC. The influence oforal contraceptives on the risk of multiple sclerosis. Br. J. Obstet. Gynaecol. 105, 1296-1299 (1998).
106. o6 Hernan MA, Olek MJ, Ascherio A. Cigarette smoking and incidence of multiple sclerosis. Am. J. Epidemiol. 154, 69-74 (2001).
107. Hernan MA, Jick SS, Logroscino G et al. Cigarette smoking and the progression of multiple sclerosis. Brain 128, 1461-1465 (2005).
108. Bass NH. Pathogenesis of myelin lesions in experimental cyanide encephalopathy. A microchemical study. Neurology 18, 167-177 (1968).
109. Lessell S. Experimental cyanide optic neuropathy. Arch. Ophthalmol. 86, 194-204 (1971).
110. Chen JL, Wei L, Bereczki D et al. Nicotine raises the influx of permeable solutes across the rat blood-brain barrier with little or no capillary recruitment. J. Cereb. Blood Flow Metab. 15, 687-698 (1995).
111. Sopori ML, Kozak W. Immunomodulatory effects of cigarette smoke. J. Neuroimmunol. 83, 148-156 (1998).